1034156-00-7

Basic information

• Product Name: (1R,2S)-2-amino-1-(3-methoxyphenyl)propan-1-ol hydrochloride
• Synonyms: (1R,2S)-2-amino-1-(3-methoxyphenyl)propan-1-ol hydrochloride
• CAS NO: 1034156-00-7
• Molecular Weight: 217.696
• Mol File: 1034156-00-7.mol

Chemical Properties

• CAS DataBase Reference: (1R,2S)-2-amino-1-(3-methoxyphenyl)propan-1-ol hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (1R,2S)-2-amino-1-(3-methoxyphenyl)propan-1-ol hydrochloride(1034156-00-7)
• EPA Substance Registry System: (1R,2S)-2-amino-1-(3-methoxyphenyl)propan-1-ol hydrochloride(1034156-00-7)

Safety Data

• Hazardous Substances Data: 1034156-00-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(1R,2S)-2-amino-1-(3-methoxyphenyl)propan-1-ol hydrochloride serves as a crucial chiral building block for the synthesis of various pharmaceutical compounds. Its application is particularly relevant in the development of drugs aimed at treating neurological and psychiatric disorders, where the compound's unique stereochemistry can contribute to the efficacy and safety of the resulting medications.
Used as a Chiral Synthon:
In the field of organic chemistry and drug development, (1R,2S)-2-amino-1-(3-methoxyphenyl)propan-1-ol hydrochloride is utilized as a chiral synthon. This means it is employed as an intermediate in the synthesis of enantiomerically pure compounds, which is essential for creating drugs with targeted effects and minimized side effects.
Used for Enhanced Stability and Solubility:
The hydrochloride salt form of (1R,2S)-2-amino-1-(3-methoxyphenyl)propan-1-ol is applied to improve the stability and solubility of the compound. This enhancement is critical for pharmaceutical applications, as it can affect the compound's performance, bioavailability, and overall suitability as a drug substance.
Used in the Production of Enantiomerically Pure Drug Substances:
Due to its chiral nature, (1R,2S)-2-amino-1-(3-methoxyphenyl)propan-1-ol hydrochloride is instrumental in the production of enantiomerically pure drug substances. These pure forms of drugs can possess better pharmacological properties and reduced side effects, offering significant advantages over racemic mixtures in terms of safety and efficacy.

Upstream product

• 1034153-26-8 tert-butyl N-[(1S,2R)-2-hydroxy-2-(3-methoxyphenyl)-1-methyl-ethyl] carbamate 

Downstream Products

• 1417334-60-1 N-[(1S,2R)-2-hydroxy-2-(3-methoxyphenyl)-1-methyl-ethyl]-4-nitro-benzene sulfonamide 
• 1034153-23-5 (1R,2S)-1-((1-(4-fluorophenyl)-1H-indazol-5-yl)oxy)-1-(3-methoxyphenyl)propan-2-amine 

Relevant articles and documents

Selective Nonsteroidal Glucocorticoid Receptor Modulators for the Inhaled Treatment of Pulmonary Diseases

A class of potent, nonsteroidal, selective indazole ether-based glucocorticoid receptor modulators (SGRMs) was developed for the inhaled treatment of respiratory diseases. Starting from an orally available compound with demonstrated anti-inflammatory activity in rat, a soft-drug strategy was implemented to ensure rapid elimination of drug candidates to minimize systemic GR activation. The first clinical candidate 1b (AZD5423) displayed a potent inhibition of lung edema in a rat model of allergic airway inflammation following dry powder inhalation combined with a moderate systemic GR-effect, assessed as thymic involution. Further optimization of inhaled drug properties provided a second, equally potent, candidate, 15m (AZD7594), that demonstrated an improved therapeutic ratio over the benchmark inhaled corticosteroid 3 (fluticasone propionate) and prolonged the inhibition of lung edema, indicating potential for once-daily treatment.

Self-assembled asymmetric catalyst engaged in a continuous-flow platform: An anti -selective catalytic asymmetric nitroaldol reaction

An anti-selective catalytic asymmetric nitroaldol reaction was manifested in a continuous-flow platform. The requisite Nd/Na heterogeneous catalyst was readily prepared by self-assembly of an amide-based chiral ligand, NdO 1/5(OiPr)13/5, NaHMDS, and a multiwalled carbon nanotube without covalent linkage. A stainless-steel column filled with the Nd/Na catalyst was incorporated in a flow system to promote the nitroaldol reaction with high stereoselectivity. The flow system with the heterogeneous catalyst obviated the quenching operation, and the cooling system was minimized.

CRYSTALLINE FORM OF INDAZOLYL AMIDE DERIVATIVES FOR THE TREATMENT GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS

Crystalline forms of 2,2,2-trifluoro-N-[(lR,2S)-l-[l-(4-fluorophenyl)in- dazol-5-yl]oxy-l-(3-methoxyphenyl)propan-2-yl]acetamide, processes for obtaining them, pharmaceutical intermediates used in their manu? facture, pharmaceutical compositions containing them, and their use in medical treatment.